The Efficacy of Spiramycin-based Triple Therapy for First-Line Helicobacter Pylori Eradication
DOI:
https://doi.org/10.60988/pj.v35i4.28Keywords:
spiramycin, Helicobacter pylori, eradication, side effectsAbstract
Background/ Objectives: To evaluate the efficacy and safety of spiramycin-based triple therapy for first-line Helicobacter pylori eradication.
Materials and Methods: One hundred and twenty-two dyspeptic patients infected with H. pylori, who had not received previous eradication treatment were randomly divided into two groups. The study group of 70 patients received pantoprazole 40 mg twice a day, spiramycin 1,5 M.U.I., and metronidazole 250 mg (film-coated tablet), three times a day for 10 days. Meanwhile, the control group consisting of 52 patients received standard triple therapy with pantoprazole, clarithromycin, and amoxicillin for 14 days. One month after the completion of therapy, H. pylori status was assessed. If the test for H. pylori was negative, it was considered that eradication had been successfully performed.
Results: In the study group, H. pylori was eradicated in 52 patients (74.3%), whereas in the control group, it was eradicated in 45 of them (86.58%). Although eradication was higher in the second group, the difference between the two groups was not statistically significant (p = 0.097). Regarding the side effects of the ordered therapies, 12 (54.5%) patients were sick in the first group, while 10 (45.5%) in the second group. Common adverse effects were nausea, abdominal pain, and diarrhea. Again, there was no statistical difference between these two groups (p = 0.266).
Conclusion: In our study, it was not proven that spiramycin is more effective than clarithromycin in the eradication rate of H. pylori. No significant statistical difference was found between the study group and the control group. Also, in terms of side effects, there is no difference between the two groups.
References
Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P, Liou J.M, Schulz C., Gasbarrini A., Hunt R.H, Leja M, O’Morain C., Rugge M. Suerbaum S., Tilg H., Sugano K., El-Omar E.M. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. gutjnl-2022-327745, 2022. doi: 10.1136/gutjnl-2022-327745. Epub ahead of print. PMID: 35944925.
Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P. Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64(9),1353-67, 2015. doi: 10.1136/gutjnl-2015-309252. Epub 2015 Jul 17. PMID: 26187502; PMCID: PMC4552923.
Resuli B., Prifti S., Guma S., Stone M. Prevalence of Helicobacter pylori infection in an Albanian population. Postgrad. Med. J. 75(883), 318, 1999. PMID: 10533652; PMCID: PMC1741229.
Monno R., Volpe A., Basho M., Fumarola L., Trerotoli P., Kondili L.A., Bino S., Schinaia N., Dentico P. Albanian-Italian collaborating group. Helicobacter pylori seroprevalence in selected groups of Albanian volunteers. Infection. 36(4),345-50, 2008. doi: 10.1007/s15010-008-6338-6. Epub 2008 Jun 20. PMID: 18574555.
Katsanos K.H., Tatsioni A., Tsakiris V., Christodoulou D., Tsianos E.V. Helicobacter pylori is a major public health priority in western Balkans: an endoscopy referral center experience. Eur. J. Intern Med. 21(4), 306-9, 2010. doi: 10.1016/j.ejim.2010.04.004. PMID: 20603041.
Zhubi B., Baruti-Gafurri Z., Mekaj Y., Zhubi M., Merovci I., Bunjaku I., Topciu V., Devoli-Disha E. Helicobacter pylori infection according to ABO blood group among blood donors in Kosovo. JHSCI. 1(2),83-9, 2011.
Vishi I., Dogjani A., Gjata A., Haxhirexha K., Bendo H. Some epidemiological data about Stomach Cancer in Kosovo. AJTES, Albanian Journal of Trauma and Emergency Sutgery. 5(2),864-8, 2021.
Megraud F., Bruyndonckx R., Coenen S., Wittkop L., Huang T.D., Hoebeke M., Bénéjat L., Lehours P., Goossens H., Glupczynski Y. European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 70(10),1815-1822, 2021. doi: 10.1136/gutjnl-2021-324032. Epub 2021 Apr 9. PMID: 33837118.
Council of European Union. Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC). Official J. Eur. Communities. 45, 13– 16, 2002.
Vacek V.. Spiramycin [Spiramycin]. Cas Lek Cesk. 133(2),56-60, 1994. Czech. PMID: 8131182.
Rubinstein E., Keller N. Spiramycin renaissance. J. Antimicrob. Chemother. 42(5),572-6, 1998. doi: 10.1093/jac/42.5.572. PMID: 9848439.
Brook I. Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance. Clin. Pharmacokinet. 34(4):303-10, 1998. doi: 10.2165/00003088-199834040-00003. PMID: 9571302.
Berstad A., Berstad K., Wilhelmsen I., Hatlebakk J.G., Nesje L.B., Hausken T. Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Aliment Pharmacol. Ther. 9(2),197-200, 1995. doi: 10.1111/j.1365-2036.1995.tb00371.x. PMID: 7605862.
Olafsson S., Berstad A., Bang C.J., Nysaeter G., Coll P., Tefera S., Hatlebakk J.G., Hausken T., Olafsson T. Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole. Aliment Pharmacol. Ther. 13(5), 651-9, 1999. doi: 10.1046/j.1365-2036.1999.00517.x. PMID: 10233189.
Kalach N., Raymond J., Benhamou P.H., Bergeret M., Senouci L., Gendrel D., Dupont C. Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children. Eur. J. Pediatr. 157(7):607-8,1998. doi: 10.1007/s004310050891. PMID: 9686829.
Raymond J., Kalach N., Bergeret M., Benhamou P.H., Barbet J.P., Gendrel D., Dupont C. Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children. Antimicrob. Agents Chemother. 42(6),1334-5, 1998. doi: 10.1128/AAC.42.6.1334. PMID: 9624470; PMCID: PMC105598.
Kumazawa J., Yagisawa M. The history of antibiotics: the Japanese story. J. Infect. Chemother. 8(2),125-33, 2002. doi: 10.1007/s101560200022. PMID: 12111564.
Graham D.Y., Lu H., Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 12(4):275-8, 2007. doi: 10.1111/j.1523-5378.2007.00518.x. PMID: 17669098.
Telaku S., Zekaj S., Veliu A., Manxhuka-Kerliu S., Fejza H., Polloshka A. Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in Kosova. Turk. J. Gastroenterol. 2006;15(1): PB02/4
Telaku S., Telaku M., Behluli E., Isjanovski V., Alidema F. Impact of Lactobacillus Reuteri and Three Other Probiotics in Helicobacter Pylori Eradication. Open Access Maced. J. Med. Sci. 10(B):2215-9,2022.
